Spyre Therapeutics Inc [SYRE] stock is trading at $22.47, up 1.03%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The SYRE shares have gain 17.40% over the last week, with a monthly amount glided 46.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Spyre Therapeutics Inc [NASDAQ: SYRE] stock has seen the most recent analyst activity on September 26, 2025, when Deutsche Bank initiated its Buy rating and assigned the stock a price target of $43. Previously, Leerink Partners started tracking the stock with Outperform rating on April 08, 2025, and set its price target to $45. On March 18, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $27 on the stock. Wedbush started tracking the stock assigning a Outperform rating and suggested a price target of $45 on September 04, 2024. Evercore ISI initiated its recommendation with a Outperform. Robert W. Baird started tracking with a Outperform rating for this stock on May 02, 2024, and assigned it a price target of $50. In a note dated March 01, 2024, Wells Fargo upgraded an Overweight rating on this stock and boosted its target price from $12 to $35.
Spyre Therapeutics Inc [SYRE] stock has fluctuated between $10.91 and $40.26 over the past year. Currently, Wall Street analysts expect the stock to reach $43 within the next 12 months. Spyre Therapeutics Inc [NASDAQ: SYRE] shares were valued at $22.47 at the most recent close of the market. An investor can expect a potential return of 91.37% based on the average SYRE price forecast.
Analyzing the SYRE fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.46 and Total Capital is -0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 21.92 points at the first support level, and at 21.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.00, and for the 2nd resistance point, it is at 23.53.
Ratios To Look Out For
For context, Spyre Therapeutics Inc’s Current Ratio is 6.49. In addition, the Quick Ratio stands at 6.49 and the Cash Ratio stands at 0.98.
Transactions by insiders
Recent insider trading involved Burrows Scott L, Chief Financial Officer, that happened on Sep 02 ’25 when 18428.0 shares were sold. Director, Albers Jeffrey W. completed a deal on Nov 06 ’24 to sell 6700.0 shares. Meanwhile, Director Albers Jeffrey W. sold 300.0 shares on Oct 25 ’24.
